MOLN Share Price | Molecular Partners AG Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

12.48 k

Shareholding (Sep 2025)

FII

0.03%

Held by 1 FIIs

DII

99.97%

Held by 0 DIIs

Promoter

0.00%

Compare Molecular Partners AG with Similar Stocks

PolyPeptide Group AG Kuros Biosciences Ltd.Bachem Holding AG

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CHF 123 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.05

Return on Equity

-60.20%

Price to Book

1.29

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-20 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

4.8%

6 Months

21.42%

1 Year

-19.91%

2 Years

-11.11%

3 Years

-39.6%

4 Years

-85.4%

5 Years

-85.43%

Molecular Partners AG for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-4.13%

EBIT to Interest (avg)

-3.08

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.01

Sales to Capital Employed (avg)

0.28

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.03%

ROCE (avg)

ROE (avg)

27.79%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.04

EV to EBIT

0.04

EV to EBITDA

0.04

EV to Capital Employed

0.34

EV to Sales

-2.23

PEG Ratio

Dividend Yield

ROCE (Latest)

912.22%

ROE (Latest)

-58.30%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bearish

Moving Averages

Bullish (Daily)

KST

Bullish

Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.03%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -21.43% vs -50.00% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.10",
          "val2": "-15.60",
          "chgp": "9.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.60",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-20.40",
          "val2": "-16.80",
          "chgp": "-21.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -28.57% vs -96.31% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 12.90% vs -152.59% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5.00",
          "val2": "7.00",
          "chgp": "-28.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-58.80",
          "val2": "-58.70",
          "chgp": "-0.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-54.00",
          "val2": "-62.00",
          "chgp": "12.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-12,317.30%",
          "val2": "-8,682.60%",
          "chgp": "-363.47%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-14.10

-15.60

9.62%

Interest

0.00

Exceptional Items

-2.60

0.00

Consolidate Net Profit

-20.40

-16.80

-21.43%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -21.43% vs -50.00% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

5.00

7.00

-28.57%

Operating Profit (PBDIT) excl Other Income

-58.80

-58.70

-0.17%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-54.00

-62.00

12.90%

Operating Profit Margin (Excl OI)

-12,317.30%

-8,682.60%

-363.47%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -28.57% vs -96.31% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 12.90% vs -152.59% in Dec 2023

All Annual Results

Company CV

About Molecular Partners AG

Molecular Partners AG

Pharmaceuticals & Biotechnology

Molecular Partners AG is a Switzerland-based company engaged in the pharmaceuticals industry. As a biopharmaceutical company, it is active in the research and development of proteins like DARPins (Designed Ankyrin Repeat Proteins), a new class of small proteins used for the development of medicine against diseases like cancer and sight-threating diseases, among others. The Company’s pipeline is structured mainly through three areas: Ophthalmology, including the creation of therapies for renital diseases like wet age-related macular degeration (wet AMD) and diabetic macular edema (DME); Oncology, containing the development of DARPins against cancer, among others; and Immunology and other Indications, entailing DARPins against several targets important for the treatment of inflammatory and auto-immune diseases.

Company Coordinates

Company Details

Wagistrasse 14 , SCHLIEREN None : 8952

Tel: 41 44 75577001 420 2361

https://www.molecularpartners.com/

Registrar Details